Type 2 diabetes mellitus complicated by fatty liver
Conditions
Interventions
Type 2 diabetes patients who start on tirzepatide (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and metformin are also included in the study population in the same process)
Sponsors
JCHO Tokyo Yamate Medical Centre
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes patients over 20 years old with fatty liver detected by abdominal echo or CT scan within 1 year of study entry.
Exclusion criteria
Exclusion criteria: Alcohol consumption exceeding 20g for women or 30g for men per day. Pregnant women. Contraindication to MRI. BMI less than 18 kgm2. SGLT2 inhibitors were excluded if they were started within 1 year of study entry. Other diabetes medications were excluded for those starting within 8 weeks of study entry. Severe renal or hepatic disease. Other chronic liver disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in liver fat content, HbA1c, and BMI at 36 weeks from baseline | — |
Countries
Japan
Contacts
Public ContactAkihisa Hidaka
JCHO Tokyo Yamate Medical Centre Department of Diabetes and Endocrinology
Outcome results
None listed